EMA has published an overview of its key recommendations of 2024 regarding the authorisation and safety monitoring of veterinary medicines. 

In 2024, EMA recommended 25 veterinary medicines for marketing authorisation – the highest ever number of recommendations in a year. Of these, two had a new active substance which had not previously been authorised in a veterinary medicine in the EU. 14 were vaccines, including seven that had been developed by means of a biotechnological process.

Among the medicines recommended for marketing authorisation in 2024, 13 were for food-producing animals, such as chickens, pigs and cattle, and 11 were for companion animals, such as dogs and cats.

A selection of these recommendations can be found in the veterinary medicines highlights document published today.